FDA advisors endorse new RSV antibody drug for babies

FDA advisors recommend approval for a new RSV antibody drug to protect infants from serious lung illnesses.

Driving the news: On Thursday, the panel voted in favor of FDA approval for the injectable antibody medication called nirsevimab after testimony from drugmaker AstraZeneca, FDA scientists, and the public.
* The drug would offer babies protection during their first RSV seasons with a single shot.

The bigger picture: RSV is a viral infection that causes hospitalization for 58,000 to 80,000 young children each year, making it the leading cause of infant hospitalization in the U.S.

What’s next: The FDA is expected to make a decision in the third quarter of 2023, and if approved, the companies plan to launch the preventive shot in the U.S. ahead of the 2023-2024 RSV season.
* The antibody has already been approved in the EU and is under consideration in several Asian countries.

View original article on NPR

This summary was created by an AI system. The use of this summary is subject to our Terms of Service.

Contact us about this post






Leave a Reply

Your email address will not be published. Required fields are marked *